\
&
Contact us
\
&
Contact us
Published on | 1 hour ago
ProgrammesThe European Partnership for Personalised Medicine (EP PerMed) is about to launch the joint transnational call 2027 (JTC2027) “Cell and Gene Therapy for Personalised Medicine”. The call opens on 4 November 2026.
Proposals must focus on the development and validation of an innovative and novel cell and gene therapy for personalised medicine.
The call aims to fund multinational, innovative research projects in personalised medicine, which should bring together academic, clinical/public health and private research teams. The JTC2027 will be conducted simultaneously by the participating funding organisations in their respective region/country and coordinated centrally by the Joint Call Secretariat. The call will be implemented in two stages.
Research Foundation Flanders (FWO) plans to participate in this call. More information on available funding for researchers based in Flanders and on how to apply will become available on the FWO website upon launch of the call. Deadline for the submission of pre-proposals is 20 January 2027. Questions on available funding by FWO? Contact europe@fwo.be.
All detailed information about the call and how to apply is available on the EP PerMed dedicated webpage. A partnering tool is also available. Interested in applying? Join the information webinar on 3 December 2026 here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Funded under Horizon Europe’s Innovative Health Initiative (HORIZON-JU-IHI-2022-02-01) and running from 2023 to 2028, the iCARE4CVD project aims to improve patient care across the board, starting from those at risk of developing cardiovascular disease to those with advanced heart failure. Thomas More University of Applied Sciences plays an important role in the project focusing data analysis and AI modeling as well as on the implementation of Patient-Reported Outcome Measures and Patient-Reported Experience Measures. Find out more in the full article.
